The U.S. government has released its licensing contract with Covid-19 vaccine manufacturer, Moderna, although many of the payment details are redacted. The agreement was for Moderna to pay the U.S. National Institutes of Health (NIH) to license the spike protein technology that the pharmaceutical company used in its Covid vaccine.
For years, the drug manufacturer was hesitant to acknowledge the work that had been done by government researchers on the spike protein in its vaccine, but it finally relented in late 2021 and announced the contract on February 23.
According to the contract, Moderna paid the government a "catch-up payment" of $400 million, which was paid to the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the NIH.
The contract states that Moderna would pay the NIH a "noncreditable, nonrefundable, royalty in the amount of Four Hundred Million dollars."
Moderna had previously made a statement indicating that it would pay "low single digit loyalties" on future sales of its vaccines, but the parts of the contract that would confirm that statement has been redacted.
Many key portions of the 34-page contract are redacted
Another section reads, "The licensee agrees to pay to the NIAID earned royalties on net sales... as follows," but the remainder of the section is redacted.
The contract was obtained by The Epoch Times through the Freedom of Information Act.
The NIH cited the reasons for the redactions an exemption to the Freedom of Information Act that allows agencies to withhold "trade secrets and commercial or financial information obtained from a person and privileged or confidential."
According to James Love, director of the nonprofit Knowledge Ecology International, "It's common but [expletive] to redact royalties on a negotiated license on a government patent."
Unredacted information in the agreement indicates that Moderna agreed to pay royalties to the NIH before the contract took effect at the end of 2022. Those royalties include, "minimum annual royalty," "earned royalties," and "benchmark royalties," according to the contract.
The agreement was signed on December 14, 2022, by Michael Mowatt, Director of the Technology Transfer and Intellectual Property Office at NIAID, and Shannon Klinger, Chief Legal Officer for Moderna.
According to the agreement, payments included a royalty within 60 days after government officials gave a "reasonable detailed written statement and request" for an amount "equivalent to a pro rata share of the unreimbursed patent expenses previously paid by the NIAID."
During the pandemic, Moderna made almost $37 billion from its covid vaccines, while it has forecast $5 billion in revenue from the shots in 2023. Moderna isn't the only big pharma company to receive a massive government contract to assist with development and manufacturing. Pfizer has also been under contract with the government for its vaccine.
It is no wonder, then, why neither the government, nor the pharmaceutical companies have been keen to acknowledge, or study, the detrimental side effects like myocarditis, sudden death, and pulmonary embolism that have resulted from the vaccines in recent years.
Subscribe to our evening newsletter to stay informed during these challenging times!!